SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Chip

Chip is currently generating significant community buzz as a decentralized protocol for GPU-backed lending, with investors closely watching its potential as a financial layer for AI infrastructure. While some users are betting on the protocol's growing loan pipeline and real-world utility, others remain skeptical, leading to active debates and volatility regarding its long-term tokenomics.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group is trending as investors and community members react to reports of a signed Memorandum of Understanding between the U.S. and Iran, with intense debate centering on the geopolitical impact, market stability, and the administration's foreign policy approach. The discourse is polarized, with participants actively discussing the financial terms of the deal, potential implications for oil markets, and the broader credibility of the current leadership regarding international conflict resolution.

Avalanche is a high throughput smart contract blockchain&nbsp;platform. Validators secure the network through a proof-of-stake consensus protocol. It is said to be fast, low cost, and environmental friendly.

Avalanche

Avalanche is currently facing intense community debate as investors reconcile long-term optimism regarding its enterprise-level infrastructure usage with significant price volatility that has left many holders heavily underwater. While some market participants view the current depressed price as an asymmetric opportunity to accumulate, others remain skeptical, citing concerns over inflationary tokenomics and consistent underperformance compared to other major digital assets.

Harvest Portfolios Group Inc - Harvest Diversified High Income Shares ETF (Class A Units)

The Harvest Diversified High Income Shares ETF is seeing active interest as investors monitor its holdings during broader market volatility, with the community frequently discussing the fund's monthly distribution reliability and its role in income-focused portfolios. Investors are closely tracking updates to its underlying assets, particularly those tied to high-growth sectors, while weighing the benefits of its diversification strategy against current market trends.

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders such as Parkinson’s disease, metabolic disorders, including thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Abbvie Inc

AbbVie is trending amid reports of an $11 billion deal to acquire biotech firm Apogee Therapeutics, fueling ongoing community discussions about its aggressive M&A strategy to bolster its immunology and oncology pipelines. Investors are closely monitoring how these strategic acquisitions and potential asset integrations will impact the company's long-term growth and its ability to maintain dominance following major drug patent expirations.

ProShares Trust II - ProShares Ultra Bloomberg Crude Oil 2x Shares

ProShares Ultra Bloomberg Crude Oil

ProShares Ultra Bloomberg Crude Oil is seeing heightened attention as traders monitor fluctuating Middle East geopolitical tensions and ongoing negotiations regarding the Strait of Hormuz. The community is actively debating the impact of these developments on crude supply chains, with many focused on how potential diplomatic resolutions or continued blockades will dictate future price volatility.

Select Sector SPDR Trust (The) - State Street Energy Select Sector SPDR ETF

Energy Select Sector SPDR Fund

The Energy Select Sector SPDR Fund (XLE) is under intense scrutiny as market participants weigh geopolitical instability in the Strait of Hormuz against fluctuating diplomatic progress in Iran-U.S. negotiations. Community sentiment is deeply divided, with some investors betting on a long-term structural supply deficit caused by regional infrastructure damage, while others are wary of the extreme volatility fueled by headlines regarding supply blockades, inventory depletion, and sporadic military escalation.

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

Zebec Network is trending as investors monitor legislative developments surrounding the Clarity Act, with the community actively debating whether regulatory progress will trigger long-term adoption or if current price action remains subject to market volatility. The community sentiment is polarized between long-term holders accumulating positions based on potential institutional partnerships and skeptics focused on historical price retracements.

London-based Quant Network is set to revolutionise blockchain technology with the development of their blockchain operating system Overledger. The experienced team are determined to fulfil the original vision of the internet by creating an open trusted network for people, machines, and data to operate securely and safely.  Overledger -the first interoperable blockchain operating system that facilitates internet-scale development of decentralised, multi-chain applications. Overledger has the ability to unlock and distribute value and applications across current and future blockchains. It is an agnostic platform that connects the world's networks to blockchains and ensures you're not limited to any single a vendor or technology. Overledger is the only platform that facilitates the development of internet-scales development of decentralised, multi-chain applications.

Quant

Quant (QNT) is trending as investors focus on its role in enterprise blockchain infrastructure and RWA tokenization, with community members actively discussing upcoming staking features and the impact of the network's low token supply. While some holders express frustration over extended price consolidation, bullish sentiment remains anchored by the project's institutional partnerships and strategic positioning in the banking sector.

WeRide, Inc. operates as an investment holding company. It engages in the sale of autonomous driving vehicles, primarily including robobuses, robotaxis, robosweepers and related sensor suites. The company was founded by Tony Xu Han and Yan Li in February 2017 and is headquartered in Guangzhou, China.

WeRide Inc. - ADR

WeRide (WRD) is trending following multiple strategic partnerships, including a major collaboration with Lenovo to deploy autonomous vehicles, and robust institutional positioning evidenced by a significant stake reported by Uber. The community is actively debating the company's competitive advantage in ADAS technology versus Tesla's FSD and Waymo, while monitoring the impact of aggressive stock buybacks on price action amid high short interest.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

SYRE Completes Enrollment in SKYWAY Basket Study on SPY072, Stock Up

Spyre Therapeutics gains after completing enrollment in all SKYWAY phase II sub-studies evaluating SPY072 across three rheumatic diseases.

Upcoming Phase 2 Readouts Could Redefine These Biotech Stocks

Upcoming Phase 2 Readouts Could Redefine These Biotech Stocks $NTHI, $ORKA, $ABVX, $CGEM, $SYRE, $APGE

Spyre Therapeutics (NASDAQ:SYRE) Price Target Raised to $97.00 at Citigroup

Citigroup upped their target price on shares of Spyre Therapeutics from $64.00 to $97.00 and gave the company a "buy" rating in a research note on Wednesday...

Insider Selling: Spyre Therapeutics (NASDAQ:SYRE) CEO Sells 15,000 Shares of Stock

Spyre Therapeutics, Inc. (NASDAQ:SYRE - Get Free Report) CEO Cameron Turtle sold 15,000 shares of the company's stock in a transaction dated Friday, May 1st. The stock was sold at an average price of...

Spyre Therapeutics (NASDAQ:SYRE) Insider Sells $5,600,809.50 in Stock

Spyre Therapeutics, Inc. (NASDAQ:SYRE - Get Free Report) insider Sheldon Sloan sold 78,333 shares of Spyre Therapeutics stock in a transaction on Friday, May 1st. The shares were sold at an average...

Insider Selling: Spyre Therapeutics (NASDAQ:SYRE) CFO Sells 12,500 Shares of Stock

Spyre Therapeutics, Inc. (NASDAQ:SYRE - Get Free Report) CFO Scott Burrows sold 12,500 shares of Spyre Therapeutics stock in a transaction on Friday, May 1st. The shares were sold at an average price...

Spyre Therapeutics (NASDAQ:SYRE) Trading Down 6.3%  - Here's What Happened

Spyre Therapeutics (NASDAQ:SYRE) Trading Down 6.3% - Here's Why...

Pictet Asset Management Holding SA Cuts Stake in Spyre Therapeutics, Inc. $SYRE

Pictet Asset Management Holding SA cut its holdings in shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE - Free Report) by 11.8% during the 4th quarter, according to the company in its most recent Form...

Spyre Therapeutics (NASDAQ:SYRE) Reaches New 1-Year High - Here's What Happened

Spyre Therapeutics (NASDAQ:SYRE) Sets New 1-Year High - Still a Buy...

Universal Beteiligungs und Servicegesellschaft mbH Raises Stake in Spyre Therapeutics, Inc. $SYRE

Universal Beteiligungs und Servicegesellschaft mbH boosted its stake in Spyre Therapeutics, Inc. (NASDAQ:SYRE - Free Report) by 55.0% in the fourth quarter, according to the company in its most...

Spyre Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of next-generation human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases. Its product, Pegzilarginase, is in a Phase 3 pivotal trial for the treatment of Arginase 1 Deficiency. The company was founded by George Georgiou and David G. Lowe on December 16, 2013 and is headquartered in Waltham, MA.

Spyre Therapeutics Inc.

SYRE Stock Marks Best Session In About 3 Years — Here’s Why 

Equity

Bullish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$88.34
Prev Close	$87.49
Open	$89.55
Dividend Yield	0.00%
50-Day Moving Average	$72.73
Beta	1.78
Avg. Volume	1.03M
PE Ratio	-37.47

52-Week High	$90.99
52-Week Low	$14.00
Market Capitalization	$7.67B
EPS (Annual)	-$1.98
Price to Book	13.52
Revenue Per Employee	$0.00

SYRESpyre Therapeutics Inc

Fundamentals

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest SYRE News